1. Home
  2. SCHL vs CGEM Comparison

SCHL vs CGEM Comparison

Compare SCHL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholastic Corporation

SCHL

Scholastic Corporation

HOLD

Current Price

$39.40

Market Cap

842.4M

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.97

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCHL
CGEM
Founded
1920
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
842.4M
904.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
SCHL
CGEM
Price
$39.40
$13.97
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
$40.00
$30.13
AVG Volume (30 Days)
360.2K
873.6K
Earning Date
03-19-2026
05-11-2026
Dividend Yield
1.99%
N/A
EPS Growth
N/A
N/A
EPS
1.87
N/A
Revenue
$1,487,100,000.00
N/A
Revenue This Year
$1.88
N/A
Revenue Next Year
$4.05
$5.20
P/E Ratio
$20.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.78
$5.68
52 Week High
$43.39
$16.74

Technical Indicators

Market Signals
Indicator
SCHL
CGEM
Relative Strength Index (RSI) 49.41 45.01
Support Level $37.70 $13.75
Resistance Level $40.22 $16.21
Average True Range (ATR) 1.26 1.06
MACD -0.13 -0.11
Stochastic Oscillator 61.60 20.96

Price Performance

Historical Comparison
SCHL
CGEM

About SCHL Scholastic Corporation

Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: